- A051701 (Lymphoma)
A Randomized Phase II/III Study of Venetoclax (ABT199) plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
- NRG-GI005 COBRA (Colon)
A Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)
- NRG-GY018 (Endometrial)
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
- NRG-GY026 (Endometrial)
A Phase II/III Study of Paclitaxel/Carboplatin alone or combined with either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab and Hyaluronidase-ZZXF (Phesgo) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
- S1826 (Lymphoma)
A Phase III Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
